PropertyValue
?:abstract
  • The specific value of IgA Anti-β2glycoprotein I antibodies (aB2GP1) in the diagnosis and management of antiphospholipid syndrome (APS) is still controversial and a matter of active debate. The relevance of the IgA aB2GP1 isotype in the pathophysiology of APS has been increasingly studied in the last years. There is well know that subjects with multiple positive APS tests are at increased risk of thrombosis and/or miscarriage. However, these antibodies are not included in the 2006 APS classification criteria. Since 2010 the task force of the Galveston International Congress on APS recommends testing IgA aB2GP1 isotype in patients with APS clinical criteria in the absence of criteria antibodies. In this review, we summarize the molecular and clinical “state of the art” of the IgA aB2GP in the context of APS. We also discuss some of the characteristics that may help to evaluate the real value of the IgA aB2GP1 determination in basic research and clinical practice. The scientific community should be aware of the importance of clarifying the role of IgA aB2GP1 in the APS diagnosis.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.3390/ijms21238972
?:journal
  • Int_J_Mol_Sci
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/a500a746340dc55eed20308a7a508f2a38d7d960.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7730063.xml.json
?:pmcid
?:pmid
?:pmid
  • 33255963.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome
?:type
?:year
  • 2020-11-26

Metadata

Anon_0  
expand all